SCHLIEREN, Switzerland, Jan. 9, 2023 /PRNewswire/ -- DiNAQOR, a genetic medicine platform company, today announced that it has added to its leadership team with the appointments of two veteran biotechnology executives. Chris Rusconi, Ph.D., who brings decades of experience in global pharmaceutical development, will serve as DiNAQOR's Chief Development Officer. Steven Zelenkofske, D.O., M.S., an expert in clinical development and adaptive trial design and operations who serves on DiNAQOR's board of directors, will assume the role of Chief Strategy Officer.
ZURICH-SCHLIEREN, Switzerland and LAGUNA HILLS, Calif., Sept. 23, 2021 /PRNewswire/ -- DiNAQOR, a genetic medicine platform company focused on addressing severe inherited cardiac diseases, today announced it has expanded its leadership team by appointing veteran medical device leader Mark Dehdashtian to serve as Executive Vice President, Medical Devices.
SAN RAFAEL, Calif., May 3, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR), a gene therapy platform company, to develop novel gene therapies to treat rare genetic cardiomyopathies. DiNAQOR will receive an undisclosed upfront payment and is eligible to receive development, regulatory and commercial milestones on product sales in addition to tiered royalties on worldwide sales. The company did not disclose financial terms. BioMarin management reiterated its 2020 GAAP net income guidance of $20 to $80 million, inclusive of this collaboration.